Atossa Therapeutics is advancing (Z)-endoxifen research into McCune-Albright syndrome and Duchenne muscular dystrophy, expanding its rare-disease pipeline. The

Atossa Therapeutics is advancing (Z)-endoxifen research into McCune-Albright syndrome and Duchenne muscular dystrophy, expanding its rare-disease pipeline. The move builds on prior omics and organoid work as treatment options remain limited.